10/667,111

Sep-19-2005 02:00pm

-2-

PC25382A

Amendments to the Claims:

1. (Original Currently Amended) A compound of formula (I).

wherein

m is 1, 2 or 3;

R1 is methyl, chloro, bromo or fluoro;

 R^2 is $-Q^1-Q^2-Q^3-Q^4$ or (C_1-C_6) alkyl,

- said (C₁-C₆)alkyl is substituted with one to three OR⁴, COOR⁴, NR⁴R⁵, NRC(=O)R⁴, C(=O)NR⁴R⁵ or SO₂NR⁴R⁵;
- R^4 is (C_1-C_6) alkyl substituted with one to three F, CN, S(=0) R^6 , SO₃H, SO₂ R^6 , SR⁷, C(=0)-NH-SO₂-CH₃, C(=0) R^7 , NR C(=0) R^7 , NR SO₂ R^6 , C(=0)NR R^8 , O-C(=0)NR R^8 or SO₂NR R^8 ;
- R⁵ is H or (C₁-C₆)alkyl optionally substituted with one to three F, CN, S(=O)R⁶, SO₃H, SO₂R⁶, SR⁷, C(=O)-NH-SO₂-CH₃, C(=O)R⁷, NR C(=O)R⁷, NR SO₂R⁶, C(=O)NR⁷R⁸, O-C(=O)NR⁷R⁸ or SO₂NR⁷R⁸; or
- said (C₁-C₆)alkyl is
 - 1) substituted with one to three OC(=O)R^{4a}, SR^{4a}, S(=O)R³, C(=NR⁹)R^{4a}, C(=NR⁹)-NR^{4a}R^{5a}, NR-C(=NR⁹)-NR^{4a}R^{5a}, NR-C(=O)-NR^{4a}R^{5a}, NR-C(=O)-NR^{4a}R^{5a}, NR-C(=NR⁹)-R^{4a} or NR-SO₂-R³; and
 - 2) optionally substituted with one or two OR^{4a}, COOR^{4a}, C(=O)-R^{4a}, NR^{4a}R^{5a}, NRC(=O)R^{4a}, C(=O)NR⁴R^{5a} or SO₂NR^{4a}R^{5a}:
- R⁹ is H, CN, OH, OCH₃, SO₂CH₃, SO₂NH₂ or (C₁-C₆)alkyl; and
- R^3 is (C_1-C_6) alkyl optionally substituted with one to three F, CN, S(=0)R⁶, SO₃H, SO₂R⁶, C(=0)-NH-SO₂-CH₃, OR⁷, SR⁷, COOR⁷, C(=0)R⁷, O-C(=0)NR⁷R⁸, NR⁷R⁸, NR C(=0)R⁷, NR SO₂R⁶, C(=0)NR⁷R⁸ or SO₂NR⁷R⁸;

-3-

PC25382A

P.008

T-863

• R⁴ⁿ and R^{5a} are the same or different and are H or (C₁-C₆)alkyl optionally substituted with one to three F, CN, S(=0)R⁶, SO₃H, SO₂R⁶, C(=0)-NH-SO₂-CH₃, OR⁷, SR⁷, COOR⁷, C(=0)R⁷,

O-C(=O)NR⁷R⁸, NR⁷R⁸, NR¹C(=O)R⁷, NR'SO₂R⁶, C(=O)NR⁷R⁸ or SO₂NR⁷R⁸;

 Q^1 is a single bond or (C_1-C_6) alkylene;

Q² is a saturated 4- to 6-membered heterocyclyl comprising one or two O or N;

Q3 is (C1-C6)alkylene;

Q4 is a 4 to 8-membered, aromatic or non aromatic, heterocyclyl comprising 1 to 4

-O-, -S-, -S(=O)-, -SO₂- or -N-, said heterocyclyl being optionally substituted with one to three -OR, -NRR', -CN or -(C₁-C₆)alkyl;

R is H or (C_1-C_6) alkyl;

R⁶ is (C₁-C₆)alkyl optionally substituted with one or two -OR';

R⁷ and R⁸ are the same or different and are H or (C₁-C₆)alkyl optionally substituted with one or two -OR';

 R^9 is H, -CN, -OH, -OCH₃, -SO₂CH₃, -SO₂NH₂ or -(C₁-C₆)alkyl;

R' is H or (C₁-C₆)alkyl; and

R" is H or (C1-C6)alkyl;

provided that

- 1) the atom of Q² bound to Q¹ is a carbon atom; and
- 2) .the atom of Q⁴ bound to Q³ is a carbon atom;

or a racemic form, isomer, pharmaceutically acceptable salts, hydrates, solvates and polymorphs derivative-thereof.

2. (Original) A compound of claim 1 wherein R² is (C₁-C₆)alkyl substituted with -OR⁴, -COOR⁴, -NR⁴R⁵, NRC(=O)R⁴, -C(=O)NR⁴R⁵ or -SO₂NR⁴R⁵; R⁴ is (C₁-C₆)alkyl substituted with one to three -S(=O)R⁶, -SO₂R⁶, -NR²C(=O)R⁷, -NR²SO₂R⁶, -C(=O)NR⁷R⁸, -O-C(=O)NR⁷R⁸ or SO₂NR⁷R⁸; R⁵ is H or (C₁-C₆)alkyl optionally substituted with one to three -S(=O)R⁶, -SO₂R⁶, -NR²C(=O)R⁷, -NR²SO₂R⁶, -C(=O)NR⁷R⁸, -O-C(=O)NR⁷R⁸ or SO₂NR⁷R⁸; R⁶ is (C₁-C₆)alkyl; and R², R⁷ and R⁸ are the same or different and are H or (C₁-C₆)alkyl.

10/667,111

Sep-19-2005 02:01pm

-4-

PC25382A

- 3. (Original) A compound of claim 1 wherein R² is (C₁-C₄)alkyl substituted with -NR⁴R⁵ or -C(=O)NR⁴R⁵; R⁴ is (C₁-C₆)alkyl substituted with -S(=O)CH₃, -NHC(=O)CH₃ or -C(=O)NR⁷R⁸; R⁵ is H or methyl; and R⁷ and R⁸ are the same or different and are H or methyl.
- 4. (Original) A compound of claim 1 wherein R^2 is $(C_1\text{-}C_6)$ alkyl substituted with one to three $-OC(=O)R^{4a}$, $-SR^{4a}$, $-S(=O)R^3$, $-NRCOOR^{4a}$, $-NR-C(=O)-NR^{4a}R^{5a}$, $-NR-SO_2-NR^{4a}R^{5a}$ or $-NR-SO_2-R^3$; and said $(C_1\text{-}C_6)$ alkyl is optionally substituted with -OH or $-OCH_3$; R is H or CH_3 ; R^3 is $(C_1\text{-}C_6)$ alkyl optionally substituted with one to three -F, -CN, $-S(=O)R^6$, $-SO_3H$, $-SO_2R^6$, $-C(=O)-NH-SO_2-CH_3$, $-OR^7$, $-SR^7$, $-COOR^7$, $-C(=O)R^7$, $-O-C(=O)NR^7R^8$, $-NR^7R^8$, $-NR^7C(=O)R^7$, $-NR^7SO_2R^6$, $-C(=O)NR^7R^8$ or $-SO_2NR^7R^8$; R^{4a} and R^{5a} are the same or different and are H, $(C_1\text{-}C_6)$ alkyl optionally substituted with one to three -F, -CN, $-S(=O)R^6$, $-SO_3H$, $-SO_2R^6$, $-C(=O)-NH-SO_2-CH_3$, $-OR^7$, $-SR^7$, $-COOR^7$, $-C(=O)R^7$, $-O-C(=O)NR^7R^8$, $-NR^7R^8$, $-NR^7C(=O)R^7$, $-NR^7SO_2R^6$, $-C(=O)NR^7R^8$ or $-SO_2NR^7R^8$; R^6 is $(C_1\text{-}C_6)$ alkyl; and R^7 , R^7 and R^8 are the same or different and are H or $(C_1\text{-}C_6)$ alkyl.
- 5. (Original) A compound of claim 1 wherein R² is (C₁-C6)alkyl substituted with -S(=O)R³; R³ is (C₁-C6)alkyl optionally substituted with one to three -S(=O)R⁶, -SO₂R⁶, -NRⁿRⁿ, -ORⁿ, -NR˚C(=O)Rⁿ, -NR˚SO₂Rⁿ; -C(=O)NRⁿRⁿ; or -O-C(=O)NRⁿRⁿ; R⁶ is (C₁-C6)alkyl; and R˚, Rⁿ and Rⁿ are the same or different and are H or (C₁-C6)alkyl.
- 6. (Original) A compound of claim 1 wherein R^2 is (C_1-C_6) alkyl substituted with $-S(=O)R^3$; and R^3 is (C_1-C_6) alkyl, preferably methyl.
- 7. (Original) A compound of claim 1 wherein R² is Q¹-Q²-Q³-Q⁴; Q² is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom; Q³ is a linear (C₁-C₄)alkylene group; Q⁴ is a 5- or 6-membered aromatic heterocycle comprising one to four nitrogen atoms, said heterocycle being optionally substituted with methyl.

10/667,111 -5-

PC25382A

- 8. (Original) A compound of claim 1 wherein R² is Q¹-Q²-Q³-Q⁴; Q¹ is a single bond; Q² is a saturated 4 to 6-membered heterocycle comprising a nitrogen atom; Q³ is -CH₂-; and Q⁴ is a 5-membered, aromatic heterocycle comprising 2 nitrogen atoms, said heterocycle being optionally substituted with methyl.
- 9. (Original) A compound of claim 8 wherein R¹ is -Cl or -F.

PATENT PFIZER ANN ARBOR MI

- 10. (Original) A compound of claim 8 wherein m is 2.
- 11. (Original Currently Amended) A compound according to claim 8 and selected from 5'-(2-[(2-amino-2-oxoethyl)amino]ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;
 - 8'-chloro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;
 - 5'-(2-{[2-(acetylamino)ethyl]amino}ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;
 - 8'-fluoro-5'-[3-(methylsulfinyl)propoxy]-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;
 - 8'-fluoro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one: or
 - 8'-fluoro-5'-(2-{[1-(1H-pyrazol-3-ylmethyl)azetidin-3-yl]oxy}1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one.
- 12. (Original Canceled)

 A method of treating a disease for which PDE7 inhibition therapy is indicated in a mammal comprising administering to said mammal in need thereof a compound of claim 1.
- 13. (Original Currently Amended) A method of claim 12 wherein said treating a disease is selected from T-cell-related diseases, autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple selectesis, osteoporosis, chronic obstructive pulmonary disease (COPD), asthma, cancer, leukemia, acquired immune deficiency syndrome (AIDS),

10/667,111

-6-

PC25382A

allergy, inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, panereatitis, dermatoses, psoriasis, atopic dermatitis, glomerulonephritis, conjunctivitis, autoimmuno diaboto, graft rejection, epilepsy, muscular atrophy and systemic lupus erythematosus in a mammal comprising administering to said mammal in need thereof, a compound of claim1.

- 14. (Original) A method of claim 13 wherein said disease is asthma, allergy or atopic dermatitis.
- 15. (Original) A method of claim 13 wherein said disease is osteoporosis.
- 16. (Original) A method of claim 13 wherein said disease is cancer.
- 17. (Original) A pharmaceutical composition comprising a compound of claim 1 together with a pharmaceutically acceptable carrier, excipient, diluent or delivery system.